We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

GYNECARE PROSIMA* Pelvic Floor Repair System for Pelvic Organ Prolapse

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00521066
First Posted: August 27, 2007
Last Update Posted: May 6, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Ethicon, Inc.
August 24, 2007
August 27, 2007
May 6, 2014
June 2007
October 2008   (Final data collection date for primary outcome measure)
Success based on overall POP-Q score at 12 months post-procedure. [ Time Frame: 12-months ]
Success is determined by achievement of an overall POP-Q score of ICS Stage ≤1, without further re-intervention for POP.
POP-Q score at 12 months post-procedure. [ Time Frame: 12-months ]
Complete list of historical versions of study NCT00521066 on ClinicalTrials.gov Archive Site
  • Success based on overall POP-Q score at 24 months post-procedure. [ Time Frame: 24 months ]
    Success is determined by achievement of an overall POP-Q score of ICS Stage ≤1, without further re-intervention for POP
  • Success based on treated compartment ICS POP-Q stage [ Time Frame: 12 months ]
    Success will be determined by achievement of treated compartment POP-Q score of ICS Stage ≤1, without further re-intervention for POP.
  • Success based on treated compartment ICS POP-Q stage [ Time Frame: 24 months ]
    Success will be determined by achievement of treated compartment POP-Q score of ICS Stage ≤1, without further re-intervention for POP.
  • Success defined as the leading edge within the hymen [ Time Frame: 12 months ]
    Success defined as the leading edge within the hymen (i.e. all POP-Q values to be less than 0, without further re-intervention for POP)
  • Success defined as the leading edge within the hymen [ Time Frame: 24 months ]
    Success defined as the leading edge within the hymen (i.e. all POP-Q values to be less than 0, without further re-intervention for POP)
  • Mean PFDI-20 score [ Time Frame: 12 months ]
  • Mean PFDI-20 score [ Time Frame: 24 months ]
  • Mean change from baseline in PFDI-20 scores [ Time Frame: 24 months ]
  • Mean change from baseline in PFDI-20 scores [ Time Frame: 12 months ]
  • Mean POPDI score [ Time Frame: 12 months ]
    POPDI is a sub score of PFDI-20
  • Mean POPDI score [ Time Frame: 24 months ]
    POPDI is a sub score of PFDI-20
  • Mean change from baseline in POPDI score [ Time Frame: 12 months ]
    POPDI is a sub scores of PFDI-20
  • Mean change from baseline in POPDI score [ Time Frame: 24 months ]
    POPDI is a sub score of PFDI-20
  • Mean CRADI score [ Time Frame: 12 months ]
    CRADI is a sub score of PFDI-20
  • Mean CRADI score [ Time Frame: 24 months ]
    CRADI is a sub score of PFDI-20
  • Mean change from baseline in CRADI score [ Time Frame: 12 months ]
    CRADI is a sub score of PFDI-20
  • Mean change from baseline in CRADI score [ Time Frame: 24 months ]
    CRADI is a sub score of PFDI-20
  • Mean UDI score [ Time Frame: 12 months ]
    UDI is a sub score of PFDI-20
  • Mean UDI score [ Time Frame: 24 months ]
    UDI is a sub score of PFDI-20
  • Mean change from baseline in UDI score [ Time Frame: 12 months ]
    UDI is a sub score of PFDI-20
  • Mean change from baseline in UDI score [ Time Frame: 24 months ]
    UDI is a sub score of PFDI-20
  • EuroQol (EQ-5D health state) change from baseline [ Time Frame: 12 months ]
  • EuroQol (EQ-5D health state) change from baseline [ Time Frame: 24 months ]
  • Mean PFIQ-7 score [ Time Frame: 12 months ]
  • Mean PFIQ-7 score [ Time Frame: 24 months ]
  • Mean change from baseline in PFIQ-7 score [ Time Frame: 12 months ]
  • Mean change from baseline in PFIQ-7 score [ Time Frame: 24 months ]
  • Mean POPIQ score [ Time Frame: 12 months ]
    POPIQ is a sub-score of PFIQ-7
  • Mean POPIQ score [ Time Frame: 24 months ]
    POPIQ is a sub-score of PFIQ-7
  • Mean change from baseline in POPIQ score [ Time Frame: 12 months ]
    POPIQ is a sub-score of PFIQ-7
  • Mean change from baseline in POPIQ score [ Time Frame: 24 months ]
    POPIQ is a sub-score of PFIQ-7
  • Mean CRAIQ score [ Time Frame: 12 months ]
    CRAIQ is a sub-score of PFIQ-7
  • Mean CRAIQ score [ Time Frame: 24 months ]
    CRAIQ is a sub-score of PFIQ-7
  • Mean change from baseline in CRAIQ score [ Time Frame: 12 months ]
    CRAIQ is a sub-score of PFIQ-7
  • Mean change from baseline in CRAIQ score [ Time Frame: 24 months ]
    CRAIQ is a sub-score of PFIQ-7
  • Mean UIQ score [ Time Frame: 12 months ]
    UIQ is a sub-score of PFIQ-7
  • Mean UIQ score [ Time Frame: 24 months ]
    UIQ is a sub-score of PFIQ-7
  • Mean change from baseline in UIQ score [ Time Frame: 12 months ]
    UIQ is a sub-score of PFIQ-7
  • Mean change from baseline in UIQ score [ Time Frame: 24 months ]
    UIQ is a sub-score of PFIQ-7
  • Mean PISQ-12 score [ Time Frame: 12 months ]
    In subjects sexually active at baseline, assessment of sexual function
  • Mean PISQ-12 score [ Time Frame: 24 months ]
    In subjects sexually active at baseline, assessment of sexual function
  • Mean change from baseline in PISQ-12 score [ Time Frame: 12 months ]
    In subjects sexually active at baseline, assessment of sexual function
  • Mean change from baseline in PISQ-12 score [ Time Frame: 24 months ]
    In subjects sexually active at baseline, assessment of sexual function
  • Incidence of new onset dyspareunia, resolution or continuance of pre-existing dyspareunia [ Time Frame: ongoing ]
  • Length of procedure [ Time Frame: perioperative ]
    From time to first incision to time of last suture used to secure VSD
  • Pain score measured using Visual Analog Scale (VAS). [ Time Frame: 24 hours post surgery and at the 3-4 week visit ]
  • Discomfort of balloon removal, measured using VAS at time of removal. [ Time Frame: 24 hrs post-surgical ]
  • Subject perception of VSD: Awareness [ Time Frame: 3-4 week visit ]
    Measured by visual analogue scale
  • Subject perception of VSD: Discomfort [ Time Frame: 3-4 week visit ]
    Measured by visual analogue scale
  • Subject perception of VSD: Acceptability of discharge [ Time Frame: 3-4 week visit ]
    Measured by visual analogue scale
  • Subject global impression [ Time Frame: 12 month visit ]
    assessed on a 5 point Likert scale
  • Subject global impression [ Time Frame: 24 month visit ]
    assessed on a 5 point Likert scale
  • Summary of ICS Stages at 6 month visit.
  • Summary of treated compartment ICS POP-Q stage at 6 and 12 months.
  • Success at 12 months, defined as the leading edge within the hymen
  • Mean scores and change from baseline in PFDI-20 scores at 6 and 12 month visits including sub scores (POPDI, CRADI and UDI).
  • Date of return to normal activities
  • EuroQol (EQ-5D health state) change from baseline at 6 and 12 months visit.
  • Mean scores and change from baseline in PFIQ-7 at 6 and 12 months visit including sub scores (POPIQ, CRAIQ and UIQ).
  • In subjects sexually active at baseline, assessment of sexual function using PISQ-12 assessed at 6 and 12 month visits (mean scores and change from baseline).
  • Incidence of new onset dyspareunia, resolution or continuance of pre-existing dyspareunia
  • Total time in the operating room.
  • Length of procedure
  • Nights in hospital
  • Pain score 24 hours post surgery and at the 3-4 week visit, measured using Visual Analog Scale (VAS).
  • Discomfort of balloon removal, measured using VAS at time of removal.
  • Subject perception of VSD by VAS at 3-4 week visit, assessing incidence of VSD displacement.
  • Balloon performance as measured by inflation volume at time of removal versus original volume used for balloon inflation.
  • Subject global impression assessed on a 5 point Likert scale at 6 and 12 month visit.
  • Comparison of POP-Q success rates in DRI versus non-DRI subjects.
  • Assessment of vaginal mesh placement using 3-D ultrasound scanning
Not Provided
Not Provided
 
GYNECARE PROSIMA* Pelvic Floor Repair System for Pelvic Organ Prolapse
A Prospective, Multi-centre Study to Evaluate the Clinical Performance of the GYNECARE PROSIMA* Pelvic Floor Repair System as a Procedure for Pelvic Organ Prolapse

The purpose of this study is to is to evaluate the success of the GYNECARE PROSIMA* system in women with symptoms for pelvic organ prolapse (POP) requiring surgical correction of POP.

(*TRADEMARK)

The GYNECARE PROSIMA* system provides a simplified mesh repair, avoiding the need for dissection outside the pelvic cavity.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Women over 18 with symptomatic pelvic organ prolapse of ICS POP-Q Stage II or III, suitable for surgical repair
Pelvic Organ Prolapse
Device: GYNECARE PROSIMA* Pelvic Floor Repair System
procedure for pelvic organ prolapse
Other Name: mesh pelvic floor repari
1
Prosima Pelvic Floor Repair System
Intervention: Device: GYNECARE PROSIMA* Pelvic Floor Repair System

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
150
June 2010
October 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Candidates with symptomatic pelvic organ prolapse of ICS POP-Q Stage II or III, suitable for surgical repair. Vaginal hysterectomy, perineal repair and/or mid urethral sling procedures for incontinence may be performed concurrently.
  • Age ≥ 18 years.
  • Agrees to participate in the study, including completion of all study-related procedures, evaluations and questionnaires, and documents this agreement by signing the Ethics Committee / IRB approved informed consent.

Exclusion Criteria:

  • Additional surgical intervention concurrent to the PROSIMA procedure (e.g. sacrocolpopexy, paravaginal repair, tubal sterilisation).
  • Previous repair of pelvic organ prolapse involving insertion of mesh.
  • Previous hysterectomy within 6 months of scheduled surgery.
  • Experimental drug or experimental medical device within 3 months prior to the planned procedure.
  • Active genital, urinary or systemic infection at the time of the surgical procedure. Surgery may be delayed in such subjects until the infection is cleared.
  • Coagulation disorder or on therapeutic anticoagulant therapy at the time of surgery.
  • History of chemotherapy or pelvic radiation therapy.
  • Systemic disease known to affect bladder or bowel function (e.g. Parkinson's disease, multiple sclerosis, spina bifida, spinal cord injury or trauma).
  • Current evaluation or treatment for chronic pelvic pain (e.g. interstitial cystitis, endometriosis, coccydynia, vulvodynia).
  • Nursing or pregnant or intends future pregnancy.
  • In the investigator's opinion, any medical condition or psychiatric illness that could potentially be life threatening or affect their ability to complete the study visits according to this protocol.
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Germany,   United Kingdom,   United States
 
 
NCT00521066
300-06-005
No
Not Provided
Not Provided
Ethicon, Inc.
Ethicon, Inc.
Not Provided
Study Director: David Robinson, M.D. Ethicon, Inc.
Ethicon, Inc.
May 2014
To Top